secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunovant, Inc. (IMVT)
CIK:        0001764013
Form:       8-K
Filed at:   2022-06-08T23:59:59+00:00
Accession:  0001764013-22-000057
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunovant gains FDA alignment for Phase 3 batoclimab trials in TED; reports FY2022 loss of $156.7M
--------------------------------------------------------------------------------

- FDA aligned on Phase 3 TED program: two placebo-controlled trials (100 patients each) initiating H2 2022; top-line data H1 2025.
- Phase 3 MG trial initiation on track by end of June 2022; top-line data expected H2 2024.
- Cash $493.8M as of March 31, 2022 provides runway into calendar year 2025.
- FY2022 net loss $156.7M ($1.43/share) vs FY2021 $107.4M ($1.22/share); R&D spend $101.8M.
- Company expects to announce two new batoclimab indications by August 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1764013/000176401322000057/0001764013-22-000057-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1764013/000176401322000057/imvt-20220608.htm
  HTML page:      https://secwatch.observer/filing/0001764013-22-000057

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer